Glucagon-like peptide 1 receptor agonist prescription linked to reduction in risk for suicidal ideation or attempts
Glucagon-like peptide 1 receptor agonist prescription linked to reduction in risk for suicidal ideation or attempts
However, the agency noted officials cannot rule out that 'a small risk may exist,' and it will continue to investigate
No increased risk for suicidal ideation seen with semaglutide versus non-GLP1R agonist antiobesity medications
FDA is investigating reports of hair loss, aspiration, and suicidal thoughts among people taking the medications
Three case reports from Iceland spurred the review; two of the cases involved Ozempic
Evidence lacking that MI makes meaningful difference to weight loss, well-being when added to behavioral weight management program
Findings seen regardless of whether a person has normal, overweight, or obese BMI at baseline